On July 14, 2026, the Federal Trade Commission announced a settlement with Caremark Rx and Zinc Health Services resolving its administrative antitrust case over rebating practices…
On July 14, 2026, the Federal Trade Commission announced a settlement with Caremark Rx and Zinc Health Services resolving its administrative antitrust case over rebating practices that allegedly inflated insulin list prices. The agency projects the resolution will lock in up to $8.5 billion in consumer savings over the next decade, marking one of the most significant enforcement actions to date against a major pharmacy benefit manager. For health-care payors, pharmacies, and drug manufacturers, the settlement is a clear signal that federal regulators intend to reshape how rebates, formulary placement, and pricing transparency operate across the pharmaceutical supply chain.
The settlement compels Caremark to implement business-practice changes aimed at lowering patient out-of-pocket costs, increasing pricing transparency, and ensuring fair treatment of community pharmacies. These conditions are notable not only for their immediate impact on insulin pricing but also for the template they establish. The required conduct remedies suggest that future PBM enforcement, whether by the FTC or by parallel state actors, will focus on similar structural concerns: the interaction between rebate arrangements and list prices, the flow of savings to patients at the pharmacy counter, and the competitive treatment of independent and community pharmacies participating in PBM networks.
The Caremark resolution follows the FTC's February 2026 settlement with Express Scripts. With two of the three largest PBMs now under negotiated conduct obligations, the administrative case proceeds solely against OptumRx. That posture underscores continued regulatory pressure on the remaining major PBM and reinforces that compliance risk in this sector is neither transitory nor limited to a single defendant. Manufacturers, plan sponsors, and specialty and community pharmacies should anticipate that contracting practices scrutinized in these matters will inform ongoing investigations, litigation strategy, and potential rulemaking.
Clients engaged with PBMs should reassess existing contracting and rebate arrangements in light of the settlement's terms. Priority areas include rebate pass-through mechanics, formulary design and exclusion practices, patient cost-sharing structures tied to list price, and pharmacy network access and reimbursement terms. Documentation practices supporting the pro-competitive rationale for existing arrangements should also be revisited, as should audit rights and transparency reporting obligations.
This alert provides general information and does not constitute legal advice. Clients should consult counsel regarding the application of these developments to their specific circumstances.